Servier Renews and Expands License to Aureus
News Mar 02, 2006
Aureus Pharma has announced that Servier has both renewed their previous license to Aureus’ AurSCOPE ADME/Drug-Drug Interactions (ADME/DDI) knowledge database and expanded the license to include AurSCOPE GPCR as well.
Servier became Aureus’ first customer of the AurSCOPE ADME/DDI knowledgebase in 2002. During the subsequent years, Aureus and Servier have collaborated closely to develop and enhance the AurSCOPE ADME/DDI.
This knowledge database contains all relevant biological and chemical information related to the metabolic properties of drugs and is designed to assist in the identification of potential drug-drug interactions.
"We have found that Aureus Pharma’s high quality ADME/ Drug-Drug Interaction knowledge databases are a source of crucial information in identifying potential adverse drug-drug interactions," said Dr. Bernard Marchand, Servier’s Director of Biopharmacy.
"We also look forward to applying the AurSCOPE GPCR knowledgebase in a variety of our disease targeted programs," added Dr. Emmanuel Canet, Vice President Research at Servier.
"We are delighted that Servier has chosen to continue their collaboration with Aureus Pharma," said Dr. Andre Michel, CEO of Aureus Pharma.
"Strong partnership with pharmaceutical companies such as Servier is strategic to Aureus in the ongoing development of solutions fitting with the needs of our end users."
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019